XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Additional Information (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]            
Revenue $ 2,218 $ 13,384 $ 6,576 $ 20,462    
Accounts receivable 2,919   2,919   $ 1,822  
Collaboration Revenue [Member]            
Disaggregation Of Revenue [Line Items]            
Revenue 2,218 13,384 3,576 20,462    
Neurocrine Biosciences [Member]            
Disaggregation Of Revenue [Line Items]            
Accounts receivable 1,624   1,624      
Deferred revenue 3,025   3,025      
Flexion [Member] | Collaboration Revenue [Member]            
Disaggregation Of Revenue [Line Items]            
Milestone payments     3,000      
Exclusive License to XEN901 and Exclusive License to DTCs [Member] | Neurocrine Biosciences [Member] | Collaboration Revenue [Member]            
Disaggregation Of Revenue [Line Items]            
Revenue   11,523   17,285    
Development Services Under the Initial Development Program For DTCs [Member] | Neurocrine Biosciences [Member] | Collaboration Revenue [Member]            
Disaggregation Of Revenue [Line Items]            
Revenue 617 393 617 475    
Research And Development Funding | Neurocrine Biosciences [Member] | Collaboration Revenue [Member]            
Disaggregation Of Revenue [Line Items]            
Revenue 1,601 $ 1,468 2,959 $ 2,702    
License and Collaboration Agreement [Member] | Neurocrine Biosciences [Member]            
Disaggregation Of Revenue [Line Items]            
Upfront payment received in cash           $ 30,000
Upfront payment received in equity investment           20,000
Equity investment measured at fair value           16,667
Collaborate agreement premium related to equity investment           3,333
Transaction price allocated to performance obligations           33,333
Variable consideration allocated to performance obligation     $ 592      
Percentage of option to co-fund development costs upon achievement of certain milestones     50.00%      
License and Collaboration Agreement [Member] | Exclusive License to XEN901 and Exclusive License to DTCs [Member] | Neurocrine Biosciences [Member]            
Disaggregation Of Revenue [Line Items]            
Transaction price allocated to performance obligations           $ 28,807
License and Collaboration Agreement [Member] | Development Services Under the Initial Development Program For DTCs [Member] | Neurocrine Biosciences [Member]            
Disaggregation Of Revenue [Line Items]            
Transaction price allocated to performance obligations         $ 5,118  
Asset Purchase Agreement [Member] | Flexion [Member]            
Disaggregation Of Revenue [Line Items]            
Milestone payment due on initiation of Phase 1b clinical trial     $ 2,000      
Asset Purchase Agreement [Member] | Flexion [Member] | XEN402 [Member]            
Disaggregation Of Revenue [Line Items]            
Milestone payments     1,000      
Asset Purchase Agreement [Member] | Eligible to Receive Development Milestone Payment [Member] | Flexion [Member] | XEN402 [Member] | Maximum [Member]            
Disaggregation Of Revenue [Line Items]            
Potential milestone payments receivable 5,000   5,000      
Asset Purchase Agreement [Member] | Future Clinical Development And Global Regulatory Approval Milestone Payments [Member] | Flexion [Member] | XEN402 [Member] | Maximum [Member]            
Disaggregation Of Revenue [Line Items]            
Potential milestone payments receivable 40,750   40,750      
Asset Purchase Agreement [Member] | Commercial Milestone Payments [Member] | Flexion [Member] | XEN402 [Member] | Maximum [Member]            
Disaggregation Of Revenue [Line Items]            
Potential milestone payments receivable $ 75,000   $ 75,000